Citations

Clear

6273 citation(s) found for "To, Andrew".

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials
Bottomley, Andrew , Pe, Madeline , Sloan, Jeff A. , Basch, Ethan , Bonnetain, Franck, Calvert, Melanie , Campbell, Alicyn, Cleeland, Charles S. , Cocks, Kim , Collette, Laurence , Dueck, Amylou C. , Flechtner, Hans‐Henning , Gotay, Carolyn , Greimel, Eva , Griebsch, Ingolf , Grøenvold, Mogens , Hamel, Jean-François, King, Madeleine , Koller, Michael , Malone, Daniel C. , Martinelli, Francesca , Moinpour, Carol M. , Musoro, Jammbe , O’Connor, Daniel , Oliver, Kathy , Piault‐Louis, Elisabeth, Piccart, Martine , Pimentel, Francisco , Quinten, Chantal , Reijneveld, Jaap C. , Soltys, Katherine M, Sridhara, Rajeshwari , Taphoorn, Martin , Velikova, Galina , Coens, Corneel , Sloan, Jeff, Flechtner, Hans-Henning , Dueck, A. C. , Basch, Ethan , Devlin, Nancy J. , Kluetz, Paul Gustav , Mitchell, Sandra A , Schürmann, Christoph, Smith, Ashley Wilder

Mayo Clinic

Clinical Trials | August 24, 2018 | Volume: 15 | Issue: 6 | Pages: 624-630

10.1177/1740774518795637 | PMID 30141714 Get It

Background There is currently a lack of consensus on how health-related quality of life and other patient-reported outcome measures in cancer randomized clinical trials are analyzed and interpreted. This makes it difficult to compare results across randomized controlled trials (RCTs) synthesize scientific research, and use that evidence to inform product labeling, clinical guidelines, and health policy. The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data for Cancer Clinical Trials (SISAQOL) Consortium aims to develop guidelines and recommendations to standardize analyses of patient-reported outcome data in cancer RCTs. Methods and Results Members from the SISAQOL Consortium met in January 2017 to discuss relevant issues. Data from systematic reviews of the current state of published research in patient-reported outcomes in cancer RCTs indicated a lack of clear reporting of research hypothesis and analytic strategies, and inconsistency in definitions of terms, including “missing data,”“health-related quality of life,” and “patient-reported outcome.” Based on the meeting proceedings, the Consortium will focus on three key priorities in the coming year: developing a taxonomy of research objectives, identifying appropriate statistical methods to analyze patient-reported outcome data, and determining best practices to evaluate and deal with missing data. Conclusion The quality of the Consortium guidelines and recommendations are informed and enhanced by the broad Consortium membership which includes regulators, patients, clinicians, and academics.
Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin
Schreier, Diana J., Sakhuja, Ankit , Mara, Kristin C. , Tootooni, M. Samie , Personett, Heather A. , Nelson, Sarah , Steckelberg, James M., Tande, Aaron J. , Frazee, Erin N. , Tootooni, Mohammad S, Tande, Aaron , Mara, Kristin C , Kashani, Kianoush , Rule, Andrew D.

Mayo Clinic

Clinical Infectious Diseases | August 22, 2018 | Volume: 68 | Issue: 9 | Pages: 1456-1462

10.1093/cid/ciy724 | PMID 30165426 Get It

AbstractBackgroundNephrotoxins contribute to 20%–40% of acute kidney injury (AKI) cases in the intensive care unit (ICU). The combination of piperacillin-tazobactam (PTZ) and vancomycin (VAN) has been identified as nephrotoxic, but existing studies focus on extended durations of therapy rather than the brief empiric courses often used in the ICU. The current study was performed to compare the risk of AKI with a short course of PTZ/VAN to with the risk associated with other antipseudomonal β-lactam/VAN combinations.MethodsThe study included a retrospective cohort of 3299 ICU patients who received ≥24 but ≤72 hours of an antipseudomonal β-lactam/VAN combination: PTZ/VAN, cefepime (CEF)/VAN, or meropenem (MER)/VAN. The risk of developing stage 2 or 3 AKI was compared between antibiotic groups with multivariable logistic regression adjusted for relevant confounders. We also compared the risk of persistent kidney dysfunction, dialysis dependence, or death at 60 days between groups.ResultsThe overall incidence of stage 2 or 3 AKI was 9%. Brief exposure to PTZ/VAN did not confer a greater risk of stage 2 or 3 AKI after adjustment for relevant confounders (adjusted odds ratio [95% confidence interval] for PTZ/VAN vs CEF/VAN, 1.11 [.85–1.45]; PTZ/VAN vs MER/VAN, 1.04 [.71–1.42]). No significant differences were noted between groups at 60-day follow-up in the outcomes of persistent kidney dysfunction (P = .08), new dialysis dependence (P = .15), or death (P = .09).ConclusionShort courses of PTZ/VAN were not associated with a greater risk of short- or 60-day adverse renal outcomes than other empiric broad-spectrum combinations.
Revitalized and synovialized allograft for intrasynovial flexor tendon reconstruction in an in vivo canine model
Zhang, Tao , Lu, Cheng‐Chang , Reisdorf, Ramona L., Thoreson, Andrew R. , Gingery, Anne , Moran, Steven L. , Amadio, Peter C. , Zhao, Chunfeng , Gingery, Anne

Mayo Clinic

Journal of Orthopaedic Research | August 22, 2018 | Volume: 36 | Issue: 8 | Pages: 2218-2227

10.1002/jor.23889 | PMID 29575268 Get It

ABSTRACTThis study was to test our hypothesis that flexor tendon reconstruction with an allograft revitalized with bone marrow stromal cells (BMSCs) and synovialized with carbodiimide derivatized autologous synovial fluid (cd‐SYN) would result in better digit functional restoration than the conventional allograft tendon. A total of 32 flexor digital profundus tendons from the second and fifth digit of 16 dogs were created a repair failure model first. Then, failed‐repaired tendons were reconstructed with either a revitalized‐synovialized allograft tendon or a clinical standard autograft tendon (control group). The allograft tendon was seeded with autologous BMSCs in multiple slits and the graft surface was coated with cd‐SYN. A 6 weeks after tendon reconstruction, the digits were harvested and evaluated for digit function, adhesion status, tendon gliding resistance, attachment strength, cell viability, and histologic factors. The allograft group had significantly improved digit function compared with the control group through decreased work of flexion, increased digit range of motion under 2‐Newton force, and less adhesion score (p < .05). However, the distal attachment‐site strength and stiffness in the allograft tendon were significantly weaker than the autografts (p < .05). No significant difference was found for gliding resistance. Histologically, allograft tendons coated with allograft had smoother surfaces and showed tendon‐to‐bone and tendon‐to‐tendon incorporation. Viable BMSCs were found in the tendon slits 6 weeks after the graft. In conclusion, cellular lubricant‐based modification of allograft tendons improved digit function and reduced the adhesions compared with autograft for flexor tendon reconstruction. However, improvement of graft‐to‐host tendon healing is still challenging. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:2218–2227, 2018.
Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing
Lanktree, Matthew B. , Haghighi, Amirreza , Guiard, Elsa, Iliuta, Ioan-Andrei, Song, Xuewen , Harris, Peter C. , Paterson, Andrew D. , Pei, York , Harris, Peter C , Paterson, Andrew

Mayo Clinic

Journal of the American Society of Nephrology | August 22, 2018 | Volume: 29 | Issue: 10 | Pages: 2593-2600

10.1681/asn.2018050493 | PMID 30135240 Get It

Background Estimating the prevalence of autosomal dominant polycystic kidney disease (ADPKD) is challenging because of age-dependent penetrance and incomplete clinical ascertainment. Early studies estimated the lifetime risk of ADPKD to be about one per 1000 in the general population, whereas recent epidemiologic studies report a point prevalence of three to five cases per 10,000 in the general population. Methods To measure the frequency of high-confidence mutations presumed to be causative in ADPKD and autosomal dominant polycystic liver disease (ADPLD) and estimate lifetime ADPKD prevalence, we used two large, population sequencing databases, gnomAD (15,496 whole-genome sequences; 123,136 exome sequences) and BRAVO (62,784 whole-genome sequences). We used stringent criteria for defining rare variants in genes involved in ADPKD ( PKD1 , PKD2 ), ADPLD ( PRKCSH , SEC63 , GANAB , ALG8 , SEC61B , LRP5 ), and potential cystic disease modifiers; evaluated variants for quality and annotation; compared variants with data from an ADPKD mutation database; and used bioinformatic tools to predict pathogenicity. Results Identification of high-confidence pathogenic mutations in whole-genome sequencing provided a lower boundary for lifetime ADPKD prevalence of 9.3 cases per 10,000 sequenced. Estimates from whole-genome and exome data were similar. Truncating mutations in ADPLD genes and genes of potential relevance as cyst modifiers were found in 20.2 cases and 103.9 cases per 10,000 sequenced, respectively. Conclusions Population whole-genome sequencing suggests a higher than expected prevalence of ADPKD-associated mutations. Loss-of-function mutations in ADPLD genes are also more common than expected, suggesting the possibility of unrecognized cases and incomplete penetrance. Substantial rare variation exists in genes with potential for phenotype modification in ADPKD.
rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology
Kelemen, Linda E. , Earp, Madalene A. , Chenevix‐Trench, Georgia , Group, On behalf of Australian Ovarian Cancer Study, Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Hein, Alexander , Lambrechts, Diether , Lambrechts, Sandrina, Nieuwenhuysen, Els Van , Vergote, Ignace , Rossing, Mary Anne, Chang‐Claude, Jenny , Moysich, Kirsten, Cannioto, Rikki , Lele, Shashikant , Odunsi, Kunle , Goodman, Marc T. , Shvetsov, Yurii B. , Thompson, Pamela J., Dörk, Thilo , Antonenkova, Natalia, Bogdanova, Natalia , Hillemanns, Peter , Runnebaum, Ingo B. , Harter, Philipp , Heitz, Florian , Schwaab, Ira, Edwards, Robert P., Kelley, Joseph L., Ness, Roberta B., Lester, Jenny, Oršulić, Sandra , Walsh, Christine M. , Jensen, Allan , Cunningham, Julie M. , Vierkant, Robert A. , Bruinsma, Fiona , Hildebrandt, Michelle, Liang, Dong , Lu, Karen H., Wu, Xifeng , Sellers, Thomas A. , Schildkraut, Joellen M. , Iversen, Edwin S., Terry, Kathryn L. , Tworoger, Shelley S. , Thomsen, Liv Vestrheim, Krakstad, Camilla , Tangen, Ingvild L. , Aben, Katja K.H. , Massuger, Leon F.A.G. , Altena, Anne M. van , Bean, Yukie T., Kellar, Melissa, Le, Nhu D. , Brooks‐Wilson, Angela , Jakubowska, Anna , Lubiński, Jan , Wentzensen, Nicolas , Brinton, Louise A. , Lissowska, Jolanta , Høgdall, Estrid , Engelholm, Svend Aage, Høgdall, Claus , Lundvall, Lene, Nedergaard, Lotte , Dicks, Ed , Song, Honglin , McNeish, Iain A. , Carty, Karen , Eccles, Diana , Whittemore, Alice S. , McGuire, Valerie , Rothstein, Joseph H. , Sieh, Weiva , Narod, Steven A., Phelan, Catherine, McLaughlin, John, Ziogas, Argyrios, Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Wu, Anna H. , Pearce, Celeste Leigh, Lee, Alice W. , Pike, Malcolm C. , Kupryjańczyk, Jolanta , Podgórska, Agnieszka , Plisiecka-Hałasa, Joanna, Sawicki, Włodzimierz , Goode, Ellen L. , Berchuck, Andrew, Lu, Karen H. , Lambrechts, Diether , Earp, Madalene, Hein, Alexander , Behrens, Sabine , Hillemanns, Peter , Nevanlinna, H , Kjaer, Susanne K , Jensen, Allan , Cunningham, Julie M , Vierkant, Robert A , Bjorge, Line , Gronwald, Jacek , Brinton, Louise A , Pharoah, Paul D P , Tyrer, Jonathan P. , McNeish, Iain A , Eccles, Diana , Menon, Usha , Ramus, Susan J , Dörk, Thilo , Lambrechts, Diether , Tworoger, Shelley S , Moysich, Kirsten , Lissowska, Jolanta , Brooks-Wilson, Angela R , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T , Fridley, Brooke L. , Group, On behalf of Australian Ovarian Cancer Study, Doherty, Jennifer A. , Behrens, Sabine , Moysich, Kirsten B. , Wilkens, Lynne R. , Bois, Andreas du , Bützow, Ralf C. , Pelttari, Liisa M. , Nevanlinna, Heli , Modugno, Francesmary , Karlan, Beth Y. , Walsh, Christine, Kjær, Susanne K. , Giles, Graham G. , Southey, Melissa C. , Levine, Douglas A. , Cramer, Daniel W. , Poole, Elizabeth M. , Bandera, Elisa V. , Olson, Sara H. , Orlow, Irene , Thomsen, Liv Cecilie Vestrheim , Bjørge, Line , Kiemeney, Lambertus A. , Pejovic, Tanja B. , Cook, Linda S. , Gronwald, Jacek , Cybulski, Cezary , Pharoah, Paul D.P. , Siddiqui, Nadeem , Glasspool, Rosalind , Paul, James , Campbell, Ian , McLaughlin, John, Risch, Harvey A. , Anton‐Culver, Hoda , Gentry‐Maharaj, Aleksandra

Mayo Clinic

International Journal of Molecular Sciences | August 21, 2018 | Volume: 19 | Issue: 9 | Pages: 2473

10.3390/ijms19092473 | PMID 30134598 Get It

Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis. TYMS expression is regulated by its antisense mRNA, ENOSF1. Disrupted regulation may promote uncontrolled DNA synthesis and tumor growth. We sought to replicate our previously reported association between rs495139 in the TYMS-ENOSF1 3′ gene region and increased risk of mucinous ovarian carcinoma (MOC) in an independent sample. Genotypes from 24,351 controls to 15,000 women with invasive OC, including 665 MOC, were available. We estimated per-allele odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression, and meta-analysis when combining these data with our previous report. The association between rs495139 and MOC was not significant in the independent sample (OR = 1.09; 95% CI = 0.97–1.22; p = 0.15; N = 665 cases). Meta-analysis suggested a weak association (OR = 1.13; 95% CI = 1.03–1.24; p = 0.01; N = 1019 cases). No significant association with risk of other OC histologic types was observed (p = 0.05 for tumor heterogeneity). In expression quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1 mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa (r = 0.51, p = 1.7 × 10−28), and nonsignificantly in five MOC tumors. The association results, along with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small.
The Effect of Proximal Hamate Osteotomy on Carpal Kinematics for Reconstruction of Proximal Pole Scaphoid Nonunion With Avascular Necrosis
Greene, Ryan M. , Hewett, Timothy E. , Thoreson, Andrew R. , Hooke, Alexander W. , Elhassan, Bassem T. , Hewett, Timothy, Kakar, Sanjeev , Elhassan, Bassem T.

Mayo Clinic

HAND | August 20, 2018 | Volume: 15 | Issue: 3 | Pages: 371-377

10.1177/1558944718793175 | PMID 30124083 Get It

Background: The purpose of this study is to determine the effects of proximal hamate transfer for proximal pole scaphoid reconstruction upon carpal kinematics. Methods: Eight fresh-frozen cadaveric wrists underwent evaluation of their radiocarpal and midcarpal motion after proximal hamate osteotomy. A wrist simulator was used to apply cyclical tension to the flexor carpi ulnaris (FCU), flexor carpi radialis (FCR), extensor carpi ulnaris (ECU), and extensor carpi radialis longus and brevis stitched together (ECR). Kinematic motion was captured using Moiré Phase Tracking 3-dimensional motion-tracking sensors (MPT, Metria Innovation, Inc, Milwaukee, Wisconsin) to evaluate the lunocapitate and scapholunate angles for each condition. Results: During wrist flexion-extension and radial-ulnar deviation, there were no statistically significant differences about the lunocapitate or scapholunate axis between the intact and post-hamate osteotomy conditions. Conclusions: The harvest of the proximal hamate for proximal pole scaphoid reconstruction does not appear to adversely affect wrist kinematics.
Impact of Serum Cystatin C–Based Glomerular Filtration Rate Estimates on Drug Dose Selection in Hospitalized Patients
Peters, Bradley J. , Mara, Kristin C. , Dierkhising, Ross , Frazee, Erin N. , Dierkhising, Ross A, Frazee, Erin N , Mara, Kristin C , Rule, Andrew D. , Kashani, Kianoush , Lieske, John C.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | August 18, 2018 | Volume: 38 | Issue: 10 | Pages: 1068-1073

10.1002/phar.2175 | PMID 30120844 Get It

Study Objective Serum creatinine ( S c r ) concentration is used to calculate estimated glomerular filtration rate (e GFR ) for medication dosing. Serum cystatin C (CysC) concentration has been proposed as an adjunct or alternative to S cr . This study sought to evaluate the possible impact of using CysC in eGFR equations on drug dose recommendations in hospitalized patients with infections. Design Retrospective analysis of prospectively collected data. Setting Large academic tertiary care medical center. Patients A total of 308 adults with suspected or documented infections and stable kidney function who were hospitalized between 2012 and 2015. Measurements and Main Results Standardized S c r and CysC measured at the time of antibiotic dosing were used to estimate GFR from the three Chronic Kidney Disease Epidemiology Collaborative ( CKD ‐ EPI ) equations using S c r (eGFR Cr ), CysC( eGFR CysC ), or a combination of S c r and CysC (eGFR Cr‐CysC ), and these values were compared with estimated creatinine clearance (eCl cr ) from the Cockcroft‐Gault equation (standard of care for drug dosage adjustments). The eGFR s were categorized into five common dosage adjustment strata (lower than 20, 20–49, 50–79, 80–130, and higher than 130 ml/min), and agreement between equations was tested with the weighted κ statistic. Recommended drug doses varied considerably between the eC l cr and the CKD ‐ EPI equations (weighted κ [95% confidence interval]: eGFR Cr 0.73 [0.68–0.79], eGFR CysC 0.42 [0.35–0.5], eGFR Cr‐CysC 0.65 [0.6–0.71]). If eGFR Cr, eGFR CysC , or eGFR Cr‐CysC were used instead of eC l cr to dose drugs, 11%, 12%, and 8% of doses, respectively, would be higher, and 12%, 38%, and 24% of doses, respectively, would be lower. Conclusion Significant discordance in drug doses was observed when the CKD ‐ EPI equations were used in place of eCl cr . When CysC was included in eGFR equations, recommended doses were often lower. Further study is needed to develop and test drug‐specific dosing guidelines that incorporate alternate renal biomarkers and/or more contemporary eGFR equations.
Liraglutide and Weight Loss Among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial
Sharma, Abhinav , Ambrosy, Andrew P. , McNulty, Steven E., Mentz, Robert J. , Cooper, Lauren B. , Lala, Anuradha , Groake, John D., Borlaug, Barry A. , Borlaug, Barry A , Mentz, Robert J , DeVore, Adam D. , Margulies, Kenneth B. , Hernandez, Adrian F. , Felker, G. Michael , Vader, Justin M. , Velazquez, Eric J.

Mayo Clinic

ESC Heart Failure | August 18, 2018 | Volume: 5 | Issue: 6 | Pages: 1035-1043

10.1002/ehf2.12334 | PMID 30120812 Get It

Abstract Aims Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. Methods and results The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an ‘on-treatment’ analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19–32%). Liraglutide use was associated with a significant weight reduction [liraglutide −1.00 lbs vs. placebo 2.00 lbs; treatment difference −4.10 lbs; 95% confidence interval (CI) −7.94, −0.25; P = 0.0367; percentage treatment difference −2.07%, 95% CI −3.86, −0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference −33.1 mg/dL; 95% CI −60.7, −5.6; P = 0.019). Conclusions Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.
Abstract 5268: Interactions between genetic predictors of gene expression and dietary factors associated with risk of colorectal cancer
Petersen, Paneen S., Berndt, Sonja I. , Brenner, Hermann , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Harrison, Tabitha A. , Hoffmeister, Michael , Jenkins, Mark A. , Joshi, Amit D. , Küry, Sébastien , Lindor, Noralane M. , Slattery, Martha L. , Thibodeau, Stephen N. , Peters, Ulrike , CCFR, GECCO, Hoffmeister, Michael , Jenkins, Mark A , Harrison, Tabitha A , Kury, Sebastien , Brenner, Hermann , Su, Yu-Ru , Bien, Stephanie A. , Casey, Graham , Chan, Andrew T. , Haile, Robert W. , Marchand, Loı̈c Le , Lin, Yi , Newcomb, Polly A. , Potter, John D. , Schoen, Robert E. , White, Emily E. , CCFR, GECCO

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 5268-5268

10.1158/1538-7445.am2018-5268 Get It

Abstract Genome-wide association studies of colorectal cancer (CRC) have identified over 50 susceptibility loci. These variants represent only a small fraction of total heritability for CRC. Gene-environment (GxE) interaction studies may help identify novel loci and biological interactions that give insight to the pathogenesis of CRC. Previous genome-wide GxE studies with dietary factors have identified interactions between loci and processed meat consumption and alcohol; however, limited statistical power remains a primary concern. Set-based SNP testing has the potential to increase statistical power to detect GxE interactions by aggregating functionally relevant SNPs. In this large pooled analysis using 14 case-control and nested case-control studies, we incorporated functional information from the transcriptome prediction tool, PrediXcan, into a novel set-based approach for testing GxE interactions. We used variant weights from the PrediXcan models of tissue-specific gene expression in the transverse colon as a priori variant information for a set-based GxE approach. We restricted our analysis to variants in the PrediXcan transverse colon gene models (n = 4,842). This discovery phase included 10,360 CRC and advanced adenoma cases, and 11,183 controls of European ancestry from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry. All 14 studies were analyzed together in a pooled data set using the Mixed Effects Score Tests for interactions. We tested for gene interactions with sex- and study- specific quartiles of dietary intake of red meat (servings/day), processed meat (servings/day), vegetables (servings/day), fruits (servings/day), and fiber (g/day). We detected two genes with suggestive interactions (false discovery rate (FDR) &lt; 0.2) with intake of red meat and risk of CRC: Superoxide Dismutase 2 (SOD2) and Ubiquitin Conjugating Enzyme E2 H (UBE2H). No interactions at FDR &lt; 0.2 were observed for processed meat, vegetables, fruits, or fiber. The SOD2 gene, which encodes an enzyme important in apoptotic signaling and clearing of reactive oxygen species, may regulate response to colonic exposure to heme iron or increased bile acid from high-fat content in red meat. UBE2H is part of the ubiquitin-proteasome system that has a role in Wnt signaling, which can be mediated by heme iron in red meat and is commonly found dysregulated in cancer. These findings highlight the efficacy of integrating functional information and set-based testing for novel discovery of genes interacting with known dietary risk factors of CRC. We plan to replicate these findings in additional studies. Citation Format: Paneen S. Petersen, Yu-Ru Su, Sonja I. Berndt, Stephanie A. Bien, Hermann Brenner, Graham Casey, Andrew T. Chan, Jenny Chang-Claude, Jane C. Figueiredo, Steven J. Gallinger, Robert W. Haile, Tabitha A. Harrison, Michael Hoffmeister, Mark A. Jenkins, Amit D. Joshi, Sébastien Küry, Loic Le Marchand, Yi Lin, Noralane M. Lindor, Polly A. Newcomb, John D. Potter, Robert Schoen, Martha L. Slattery, Stephen N. Thibodeau, Emily White, Li Hsu, Ulrike Peters, CCFR, GECCO. Interactions between genetic predictors of gene expression and dietary factors associated with risk of colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5268.
Abstract 5925: A novel oncolytic adenovirus for radioiodine therapy and imaging
Koodie, Lisa, Kawakami, Eriko, Caycı, Zuzan , Schumacher, Robert J., Fernández-Zapico, Martín E. , Davydova, Julia , Jacobsen, Kari L. , TAYLOR, ANDREW J. , Greeno, Edward W. , Morris, John C.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 5925-5925

10.1158/1538-7445.am2018-5925 Get It

Abstract Recently, the use of oncolytic viruses encoding the sodium-iodide symporter (NIS) has become an attractive approach to achieve radionuclide imaging of cancer. However, the potential of virus-induced NIS expression to facilitate therapy with radioactive 131I has not been fully explored. We designed a tumor-selective, infectivity-improved oncolytic adenovirus (Ad5/3-Cox2-NIS-ADP) modified to express high quantities of NIS. This virus induced radioisotope uptake in prostate and lung cancer cells and facilitated SPECT/CT imaging, but more importantly, supported the effective therapy with 131I. In our original vector, enhanced oncolysis was mediated by overexpression of adenoviral death protein (ADP). Although this structure was operative in detection and therapeutic regimens, we were concerned that the cytolytic effect of ADP may affect NIS membrane localization, and diminish its effectiveness as a theranostic tool. We therefore designed an identical Ad5/3-Cox2-NIS-ADP-deleted virus {ADP(-)} and assessed the impact of ADP on NIS expression and radioisotope uptake. Western blot and immunocytochemical analyses of pancreatic cancer cells infected with ADP(-) demonstrated higher NIS levels when compared to the ADP(+) counterpart. This correlated with an improved 125I uptake in vitro. SPECT/CT imaging studies assessing 99mTcO4- accumulation in mice to visualize pancreatic adenocarcinoma (PDAC) using patient-derived xenografts (PDX) showed that a single dose of ADP(-) accumulated far greater levels of 99mTcO4- when compared to ADP(+). Remarkably, ADP(-) produced stronger signal that was maintained up until day 32, and this outlasted ADP(+) and the control vector, replication-deficient AdCMV-NIS, currently employed in a clinical trial. Notably, within the PDAC, ADP(-) showed a distinct NIS cell membrane distribution pattern as it co-localized with cell membrane bound-cytokeratin-4. Unlike ADP(-), ADP(+) produced a punctate NIS staining pattern, with little to no cell membrane localization. These results support our hypothesis that ADP-cytolytic effect reduces NIS membrane localization, subsequently affecting radionuclide uptake. To evaluate the therapeutic potential of NIS-based radiotherapy, we treated mice bearing PDAC tumors with virotherapy alone or in combination with 131I. NIS-expressing OAds in combination with 131I significantly reduced tumor growth when compared to viro- or radiotherapy alone. The therapeutic effect in mice treated with ADP(-) combined with 131I outperformed that with ADP(+) or AdCMV-NIS vectors. Quantitative analyses of 131I uptake in tumor tissues with a gamma counter showed a clear trend where ADP(-) retained higher 131I uptake than ADP(+). These findings support the clinical applicability of the ADP-deleted OAd as the more sensitive tool for NIS-based cancer diagnosis and therapy. We are currently investigating the biodistributon and toxicity of our vectors in a pig model. Citation Format: Lisa Koodie, Eriko Iguchi Kawakami, Kari Jacobsen, Zuzan Cayci, Andrew Taylor, Edward W. Greeno, Robert J. Schumacher, John C. Morris, Martin E. Fernandez-Zapico, Julia Davydova. A novel oncolytic adenovirus for radioiodine therapy and imaging [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5925.